Zai Lab Announces NDA for Sulbactam-Durlobactam (SUL-DUR) Granted Priority Review by China’s NMPA
Jan 30, 2023
Read MoreSEC Declares That There Are Currently No Issuers at Risk of Delisting Due to the Holding Foreign Companies Accountable Act
Jan 20, 2023
Read MoreZai Lab Announces Inclusion of QINLOCK® (ripretinib) and NUZYRA® (omadacycline) in China’s National Reimbursement Drug List
Jan 18, 2023
Read MoreZai Lab and Novocure Announce Pivotal LUNAR Study in Non-Small Cell Lung Cancer Met Primary Overall Survival Endpoint
Jan 05, 2023
Read MoreZai Lab Announces the Appointment of Dr. Rafael G. Amado as President, Head of Global Oncology Research and Development
Jan 03, 2023
Read More